Pharvaris N.V. (9EN.F)
| Previous close | 18.70 |
| Open | 18.80 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 18.00 - 18.80 |
| 52-week range | 7.25 - 29.60 |
| Volume | |
| Avg. volume | 12 |
| Market cap | 1.036B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.63 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43.14 |
GlobeNewswirePharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacksExecuting from a strong financial position with cash and cash equivalents of €368 million as of March 31, 2024 ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rec
Simply Wall St.Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacksStrengthened executive committee with hiring of David Nassif, J.D., Chief Financial Officer, and Stefan Abele, Ph.D., as Chief Technical Operations OfficerUK Innovation Passport awarded to deucrictibant for both the on-demand and prophylactic treatment of HAE atta
